ClinicalTrials.govpublic full text
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
multiple myeloma, double-hit, daratumumab, bortezomib, lenalidomide, minimal residual disease, tailored maintenance therapy, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 909362
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.